SSRI Black Box Warnings

Many primary care providers struggle to balance discussing SSRI risks with informing families of their benefits. Here are some key facts to facilitate conversations with youth and families about the SSRI black box warning in youth:

Risk per FDA study:

• The U.S. Food and Drug Administration (FDA) noted a modest increase in suicidal thinking and behaviors for adolescents on SSRI antidepressants, which prompted them to add the black box warning in 2004.
  • Typically, increased suicidal thinking occurs earlier in the treatment course and within the first 3–4 months of treatment
  • The warning was revised in 2007 to focus on youth under the age of 25 (Stone, 2014).
• The identified risk was statistically significant but small; less than 1/100 children treated had an elevated risk of suicidal thinking (Dwyer, 2019).
• Complicating interpretation of these findings, the FDA warning also indicates that depression itself poses an increased risk of suicide and untreated depression can significantly contribute to suicide risk (Friedman, 2014).
• There have been variable methods of reporting and recording “suicide-related” events. These have included: short term suicidal ideation; persistent suicidal ideation; self-harm without suicide intent; self-harm with suicide intent–all of which have been identified as “suicide-related” events. 
  • This variability of definitions makes it difficult to evaluate the incidence of actual suicide-directed behaviors. 
• There were no completed suicides reported in the RCT database contributing to the black box warning (Jane Garland, 2016).

Considerations in Assessment and Management:

• Although treatment with antidepressant medication may involve risks, untreated depression may have devastating consequences. 
  • The natural course of depression will continue to place children and adults at a higher risk for suicide (Kraus, 2005).
  • Multiple studies found significant unintended reductions in mental health care after the warnings. After these reductions, there were marked increases in suicide deaths (Soumerai, 2024).
• It’s important to monitor for suicidal ideation, self-injurious thoughts, or any high-risk behaviors among youth throughout their treatment course, regardless of SSRI use. 
• If a child, adolescent, or young adult develops suicidal thoughts or behaviors while on an antidepressant, this may be due to worsening mood disorder, anxiety, difficulty coping, or the medication itself. 
  • The temporal association of the suicidal ideation or behavior to medication initiation or titration, having a good history of pre-medication suicidal thoughts and behaviors, understanding the context of thoughts and behaviors to life stressors, and understanding all potential etiologies contributing to worsening suicidal ideation or behaviors can aid in assessing the relative contribution of SSRIs to the manifestation of suicidal ideation or behavior.
• It is also important to discuss the length of time for changes to mood as well as the risks of rapidly discontinuing such medications and describe the tapering process if the medication is no longer desired. 
  • Many patients may become upset when they do not see positive effects immediately and decide to stop taking it altogether.
  • Patients may also become frustrated by side effects, where frequent check-ins and collaborative education can help mitigate patient concerns. 
  • Guidance on SSRI use, both verbally and as written education, should be given to patients receiving SSRIs to advise them of potential risks and precautions to help empower them with this information (FDA, 2018).

Hua J, Malas N, Hughes-Krieger E. SSRI Black Box Warnings. Michigan Clinical Consultation & Care. November 4, 2025. https://mc3michigan.org/clinical-pearls-faqs-ssri-black-box-warnings/.